RxDoctor Payments Data

Thomas Lang, MD

Ophthalmology · Providence, RINPI 1891772620

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 33.9% of the total. Reporting peaked in 2024 at $474 and has fallen 67.0% since, to $156 in 2025.

$1,203in general payments, 2019–2025

Across 52 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$408
  • Glaukos Corporation$307
  • Amgen$191
  • Alcon$101
  • Aerie Pharmaceuticals, Inc.$98
  • Astellas Pharma US Inc$36
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$1,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,203 in reported general payments places this provider in the 55th percentile of 69 ophthalmology providers in Rhode Island.

See all ophthalmology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$247,470
Medicare patients
1,136
Services billed
2,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost207$127,033
RestasisCyclosporine33$46,216
Latanoprost910$17,229
Dorzolamide Hcl415$13,619
Alphagan PBrimonidine Tartrate27$13,423
XiidraLifitegrast12$11,901
Brimonidine Tartrate288$11,703
Brinzolamide43$10,708
RhopressaNetarsudil Mesylate17$10,571
SimbrinzaBrinzolamide/Brimonidine Tart26$6,050
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$5,166
Timolol Maleate151$4,996
Travoprost33$4,478
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat155$3,398
Fluorometholone37$2,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$408$186,671267 claims
Bausch & Lomb Americas Inc.Xiidra$13$11,90112 claims
Aerie Pharmaceuticals, Inc.Rhopressa$98$10,57117 claims
AlconSimbrinza$101$6,05026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 69 ophthalmology providers in Rhode Island.

Other ophthalmology in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →